TrialInternational journal of clinical oncology2021

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.

Naoko Hosono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.